HALO - Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01 revenue of $230.04M misses by $1.1M
2024-02-20 16:02:47 ET
More on Halozyme Therapeutics
- Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
- Halozyme Therapeutics Q4 2023 Earnings Preview
- EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze
- Seeking Alpha’s Quant Rating on Halozyme Therapeutics
- Historical earnings data for Halozyme Therapeutics